沃森生物(300142.SZ)2021年度淨利潤預降54%–64%
格隆匯2月3日丨沃森生物(300142.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤3.65億元-4.6億元,同比下降54%–64%;扣除非經常性損益後的淨利潤5.26億元-6.2億元,同比下降13%–26%;營業收入34.3億元-34.9億元,上年同期收入為29.39億元。
2021年度業績變動影響主要因素如下:1. 公司持續加大疫苗市場拓展力度,加強營銷管理,2021年度公司自主疫苗產品銷售收入總體持續增長,其中13價肺炎球菌多糖結合疫苗銷售收入較上年同期增長約66%。
2. 公司新產品、新項目研發投入增加,積極推進重點研發項目的國內、國外臨牀試驗,研發費用較上年同期增長約 256%。
3. 公司持有已上市的嘉和生物藥業(開曼)控股有限公司股票期末價格下跌,形成報吿期內公允價值變動損失,與上年同期公允價值變動收益呈反向變動,致公司報吿期內公允價值變動收益較上年同期減少約199%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.